Outlet reports Trump circulated Washington Post story on falling drug prices, disputing who gets credit

President Donald Trump promoted a Washington Post article about falling prescription drug prices in a social-media post Saturday, according to The Guardian. The outlet reported that the post highlighted the headline “Prescription drug prices record sharpest drop in more than 60 years,” with text framing Trump as the beneficiary of the achievement rather than the prior administration.

The Guardian’s report said the social-media push came after the Washington Post published its drug-pricing finding, and that the White House did not reflect what The Guardian described as the article’s attribution of the price drop to President Joe Biden. The newspaper’s reporting characterized the credited cause as tied to actions taken during the Biden administration, while Trump’s post, as described by The Guardian, presented the decline as a result of Trump-era stewardship.

Neither The Guardian’s account nor the materials provided here include an official White House posting, a transcript, or a direct link to a White House release that confirms exactly what wording Trump’s account used or what the administration cited about the underlying drivers of the price change. As a result, the credit dispute in this story is framed as reported by The Guardian, not as an independently verified White House claim about causation.

The dispute matters because the question of “who gets credit” is tied to the underlying policy mechanism that produced the lower prices. If the decline was driven by changes associated with the Biden administration, then agencies, oversight, and future proposals may focus on whether similar steps will be continued, adjusted, or replaced. If, instead, the decline is attributable to later actions, then lawmakers and regulators may be asked to evaluate whether current approaches are responsible and whether further enforcement or rule changes are warranted.

The Washington Post headline referenced by The Guardian was described as identifying the sharpest drop in drug prices in more than 60 years, pointing to a potentially meaningful shift for household costs. Prescription drug affordability has been a sustained focus of U.S. health and economic policy, and changes in price trends often feed into federal and state debates over Medicare pricing rules, pharmacy benefit structures, and federal negotiation or pricing authority.

As reported, The Guardian said the White House circulated the headline while omitting that experts cited in the Washington Post story attributed the price decline to Biden. The Guardian did not provide here the names of all experts or the full set of causal claims, so this article limits itself to the existence of the credit dispute as described by the outlet rather than the underlying economics of drug pricing.

The next factual step, for confirming what the administration is claiming, would be review of the specific White House or presidential social-media post and any accompanying explanation from relevant agencies. With only the Guardian report included in the provided record, officials’ precise rationale and the documentary basis for the attribution dispute remain unverified in this story, pending primary confirmation from an official posting or agency release.